<DOC>
	<DOCNO>NCT00001430</DOCNO>
	<brief_summary>This randomize study combination chemotherapy ( EPOCH II ) versus EPOCH II immunotherapy peripheral blood stem cell ( PBSC ) IL-2 patient relapse Hodgkin 's non-Hodgkin 's lymphoma , untreated patient low-grade non-Hodgkin 's lymphoma . The chemotherapy entail administration multiple cycle infusional doxorubicin , etoposide vincristine chemotherapy ( total 3 ) , alternate cycle high-dose cyclophosphamide ( 3 cycle ) . Patients randomize , 2:1 basis , either receive chemotherapy undergo PBSC harvest PBSC reinfusion IL-2 follow last cycle chemotherapy . In patient , immunological monitoring NK/LAK activity , T cell number function perform . The therapy specifically targeted patient would candidate high-dose chemotherapy stem cell support .</brief_summary>
	<brief_title>A Randomized Study EPOCH II Versus EPOCH II Immunotherapy Lymphomas</brief_title>
	<detailed_description>This randomize study combination chemotherapy ( EPOCH II ) versus EPOCH II immunotherapy peripheral blood stem cell ( PBSC ) IL-2 patient relapse Hodgkin 's non-Hodgkin 's lymphoma , untreated patient low-grade non-Hodgkin 's lymphoma . The chemotherapy entail administration multiple cycle infusional doxorubicin , etoposide vincristine chemotherapy ( total 3 ) , alternate cycle high-dose cyclophosphamide ( 3 cycle ) . Patients randomize , 2:1 basis , either receive chemotherapy undergo PBSC harvest PBSC reinfusion IL-2 follow last cycle chemotherapy . In patient , immunological monitoring NK/LAK activity , T cell number function perform . The therapy specifically targeted patient would candidate high-dose chemotherapy stem cell support .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients must 18 70 year old . All stage patient low , intermediate highgrade nonHodgkin 's lymphoma , Hodgkin 's disease disease follow standard chemotherapy . Stage IIIV patient previously untreated lowgrade lymphoma untreated lowgrade progression . Patients must receive less equal 2 prior combination chemotherapy regimens , combination chemotherapy refractory disease , highdose chemotherapy stem cell rescue , may CNS involvement lymphoma . Pathology slide must review diagnosis lymphoma confirm Hematopathology Section , Laboratory Pathology , NCI . No patient history coronary artery disease angina pectoris and/or ejection fraction le 42 percent . Serum creatinine clearance great 50 cc/min , bilirubin le 2.5 u AST/ALT le 2x normal , absolute neutrophil count great 1000/mm ( 3 ) platelet count great equal 100,000/mm ( 3 ) unless due respective organ involvement tumor . Patients must ECOG performance status less equal 2 . Patients must HIV negative . Pregnant woman exclude . Patients must able give informed consent . Patients , opinion principal investigator , poor psychiatric medical risk nonmalignant systemic disease exclude . A completed eligibility form .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>IL-2</keyword>
	<keyword>Drug Resistance</keyword>
	<keyword>Continuous Infusion</keyword>
	<keyword>Peripheral Stem Cells</keyword>
	<keyword>MDR</keyword>
</DOC>